Quadria Capital: Asia’s Top Private Equity Firm Driving Healthcare Innovation

Image
  In a region teeming with economic growth and healthcare challenges, private equity in Asia has emerged as a powerful force for transformation—and Quadria Capital is leading that charge. Rather than simply injecting funds into the system, this independent private equity firm is rewriting the rules of healthcare investment with a strategy that prioritizes growth, innovation, and long-term social impact.   As one of the largest private equity firms focused exclusively on the Asia-Pacific healthcare sector, Quadria Capital is quietly yet profoundly reshaping how healthcare is delivered across Asia . But what makes them different from the typical investor? It’s not just about capital— it's about commitment, capability, and a clear vision for sustainable impact.   A Purpose-Driven Investment Strategy   Quadria Capital sees the Asia as a critical market where the right investments can make a disproportionate difference. From multi-specialty hospitals and pharmaceut...

Private Equity Investment in Singapore Post COVID-19

It will be very early to draw any conclusions about the long-term impacts of the Covid-19 crisis, but the top private equity firms in Singapore most prepared to endure this crisis will benefit more. Given the darkness surrounding the Covid-19 crisis, it is impossible to assess the longer-term impact on private equity industry performance. It will depend on the duration of the lockdown and the trend of the subsequent recovery. High-valuation deals done before the slowdown may ultimately suffer as company performance comes under pressure.

https://www.quadriacapital.com/about-us/overview

Investment

Competition for attractive deals will likely decline, to private equity’s benefits. With the public markets discouraged and potential corporate buyers holding onto their investments, private equity funds are well-positioned to be the buyer for any deal that does come up for sale.

Fund Raising

For investors who have survived the 2008-09 economic crises, the current crisis is unlikely to shake their confidence.  The drop in fund-raising this time around might be less harsh than in 2008–09 when the global total dropped more than 50%. At the same time, various structural factors could restrict the amount of new capital flowing into private equity in Singapore for some time.

Returns

Expect returns to take a hit for some time as funds mark down their portfolios in tandem with the drop in public valuations. However, the impact will be unknown for several quarters, as market-to-market moves lag public equities and PE funds report quarterly.

The COVID-19 pandemic has tested the private equity industry in an unprecedented way, restricting their ability to jump as investors everywhere remained cautious or complacent. But as the situation begins to stabilize, private equity firms in Singapore will enthusiastically reengage and help lead the recovery, applying their expertise and value-creating capabilities to stand companies back up and position them for long-term success.

Comments

Popular posts from this blog

Private Equity’s Role in Tackling Global Healthcare Inequalities

The Effect of Private Equity Investment in Asia’s Health Care Sector

Private Equity Firms in India Drive Growth in Healthcare & MedTech